Theralase Technologies (TSE:TLT)
:TLT
Want to see TSE:TLT full AI Analyst Report?
Total Valuation
Theralase Technologies has a market cap or net worth of C$60.41M. The enterprise value is C$57.27M.
Market CapC$60.41M
Enterprise ValueC$57.27M
Share Statistics
Theralase Technologies has 257,058,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding257,058,320
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Theralase Technologies’s return on equity (ROE) is -2.32 and return on invested capital (ROIC) is -186.74%.
Return on Equity (ROE)-2.32
Return on Assets (ROA)-1.18
Return on Invested Capital (ROIC)-186.74%
Return on Capital Employed (ROCE)-2.23
Revenue Per Employee58.32K
Profits Per Employee-294.34K
Employee Count14
Asset Turnover0.23
Inventory Turnover1.14
Valuation Ratios
The current PE Ratio of Theralase Technologies is ―. Theralase Technologies’s PEG ratio is 1.28.
PE Ratio―
PS Ratio51.16
PB Ratio23.49
Price to Fair Value23.49
Price to FCF-12.52
Price to Operating Cash Flow―
PEG Ratio1.28
Income Statement
In the last 12 months, Theralase Technologies had revenue of 816.47K and earned -4.12M in profits. Earnings per share was -0.02.
Revenue816.47K
Gross Profit241.51K
Operating Income-4.18M
Pretax Income-4.12M
Net Income-4.12M
EBITDA-3.91M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -3.29M and capital expenditures -48.94K, giving a free cash flow of -3.33M billion.
Operating Cash Flow-3.29M
Free Cash Flow-3.33M
Free Cash Flow per Share-0.01
Dividends & Yields
Theralase Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.20
52-Week Price Change20.51%
50-Day Moving Average0.27
200-Day Moving Average0.23
Relative Strength Index (RSI)48.56
Average Volume (3m)121.23K
Important Dates
Theralase Technologies upcoming earnings date is Aug 31, 2026, TBA (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateAug 31, 2026
Ex-Dividend Date―
Financial Position
Theralase Technologies as a current ratio of 1.25, with Debt / Equity ratio of ―
Current Ratio1.25
Quick Ratio0.94
Debt to Market Cap<0.01
Net Debt to EBITDA-0.07
Interest Coverage Ratio-99.25
Taxes
In the past 12 months, Theralase Technologies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Theralase Technologies EV to EBITDA ratio is -10.75, with an EV/FCF ratio of -12.61.
EV to Sales51.49
EV to EBITDA-10.75
EV to Free Cash Flow-12.61
EV to Operating Cash Flow-12.80
Balance Sheet
Theralase Technologies has C$182.91K in cash and marketable securities with C$431.58K in debt, giving a net cash position of -C$275.14K billion.
Cash & Marketable SecuritiesC$182.91K
Total DebtC$431.58K
Net Cash-C$275.14K
Net Cash Per Share>-C$0.01
Tangible Book Value Per Share<C$0.01
Margins
Gross margin is ―, with operating margin of -511.39%, and net profit margin of -504.71%.
Gross Margin―
Operating Margin-511.39%
Pretax Margin-504.71%
Net Profit Margin-504.71%
EBITDA Margin-478.86%
EBIT Margin-499.56%
Analyst Forecast
The average price target for Theralase Technologies is C$0.70, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$0.70
Price Target Upside150.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-9.60%
EPS Growth Forecast22.16%